Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig
In our previous study, enrofloxacin-loaded docosanoic acid solid lipid nanoparticles (SLNs) could be effectively delivered to cells in vitro. In this study, its properties and exploitation as possible oral and intramuscular sustained release formulations for pigs were studied after being made into s...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/10717544.2019.1580798 |
| _version_ | 1811213209466568704 |
|---|---|
| author | Yanfei Tao Fei Yang Kuiyu Meng Dongmei Chen Yujuan Yang Kaixiang Zhou Wanhe Luo Wei Qu Yuanhu Pan Zonghui Yuan Shuyu Xie |
| author_facet | Yanfei Tao Fei Yang Kuiyu Meng Dongmei Chen Yujuan Yang Kaixiang Zhou Wanhe Luo Wei Qu Yuanhu Pan Zonghui Yuan Shuyu Xie |
| author_sort | Yanfei Tao |
| collection | DOAJ |
| description | In our previous study, enrofloxacin-loaded docosanoic acid solid lipid nanoparticles (SLNs) could be effectively delivered to cells in vitro. In this study, its properties and exploitation as possible oral and intramuscular sustained release formulations for pigs were studied after being made into suspension. The re-dispersed time and sedimentation rate of the nanosuspension were 55 s and 1, respectively. It showed good stability when stored away from light and sustained release in pH = 7.4 PBS buffer. The suspension exhibited no irritation at the injection site and good palatability. Compared with commercial injection and soluble powder, the nanosuspension increased the bioavailability of enrofloxacin by 1.63 and 2.38 folds, and extended the mean residence time (MRT) of the drug from 11.27 and 12.33 to 37.76 and 35.15 h after intragastric and intramuscular administration, respectively. These results suggest that docosanoic acid SLN suspension (DAS) might be a promising oral and intramuscular sustained release formulation to enhance the pharmacological activity of enrofloxacin. |
| first_indexed | 2024-04-12T05:43:07Z |
| format | Article |
| id | doaj.art-628cae523a074af19c23261a17208ee1 |
| institution | Directory Open Access Journal |
| issn | 1071-7544 1521-0464 |
| language | English |
| last_indexed | 2024-04-12T05:43:07Z |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj.art-628cae523a074af19c23261a17208ee12022-12-22T03:45:34ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642019-01-0126127328010.1080/10717544.2019.15807981580798Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pigYanfei Tao0Fei Yang1Kuiyu Meng2Dongmei Chen3Yujuan Yang4Kaixiang Zhou5Wanhe Luo6Wei Qu7Yuanhu Pan8Zonghui Yuan9Shuyu Xie10Huazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityHuazhong Agricultural UniversityIn our previous study, enrofloxacin-loaded docosanoic acid solid lipid nanoparticles (SLNs) could be effectively delivered to cells in vitro. In this study, its properties and exploitation as possible oral and intramuscular sustained release formulations for pigs were studied after being made into suspension. The re-dispersed time and sedimentation rate of the nanosuspension were 55 s and 1, respectively. It showed good stability when stored away from light and sustained release in pH = 7.4 PBS buffer. The suspension exhibited no irritation at the injection site and good palatability. Compared with commercial injection and soluble powder, the nanosuspension increased the bioavailability of enrofloxacin by 1.63 and 2.38 folds, and extended the mean residence time (MRT) of the drug from 11.27 and 12.33 to 37.76 and 35.15 h after intragastric and intramuscular administration, respectively. These results suggest that docosanoic acid SLN suspension (DAS) might be a promising oral and intramuscular sustained release formulation to enhance the pharmacological activity of enrofloxacin.http://dx.doi.org/10.1080/10717544.2019.1580798enrofloxacindocosanoic acid-solid lipid nanoparticlessuspensionoral formulationintramuscular formulation |
| spellingShingle | Yanfei Tao Fei Yang Kuiyu Meng Dongmei Chen Yujuan Yang Kaixiang Zhou Wanhe Luo Wei Qu Yuanhu Pan Zonghui Yuan Shuyu Xie Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig Drug Delivery enrofloxacin docosanoic acid-solid lipid nanoparticles suspension oral formulation intramuscular formulation |
| title | Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig |
| title_full | Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig |
| title_fullStr | Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig |
| title_full_unstemmed | Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig |
| title_short | Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig |
| title_sort | exploitation of enrofloxacin loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig |
| topic | enrofloxacin docosanoic acid-solid lipid nanoparticles suspension oral formulation intramuscular formulation |
| url | http://dx.doi.org/10.1080/10717544.2019.1580798 |
| work_keys_str_mv | AT yanfeitao exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT feiyang exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT kuiyumeng exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT dongmeichen exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT yujuanyang exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT kaixiangzhou exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT wanheluo exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT weiqu exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT yuanhupan exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT zonghuiyuan exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig AT shuyuxie exploitationofenrofloxacinloadeddocosanoicacidsolidlipidnanoparticlesuspensionasoralandintramuscularsustainedreleaseformulationsforpig |